Drug Profile


Alternative Names: Anti-CD3 monoclonal antibody humanised - Protein Design Labs; HuM-291; Humanised anti-CD3 IgG2 antibody HuM291 gamma-2M3; Humanised monoclonal antibody M291; Monoclonal antibody anti-CD3 humanised; Nuvion; SMART anti-CD3 antibody; SMART anti-CD3 MAb; Visiluzumab

Latest Information Update: 10 Jul 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Graft-versus-host disease; Psoriasis; Renal transplant rejection; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 19 Dec 2007 Discontinued - Phase-II for Ulcerative colitis in Canada (IV)
  • 19 Dec 2007 Discontinued - Phase-II for Ulcerative colitis in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top